Trevi Therapeutics Inc. (TRVI)
4.26
-0.26 (-5.75%)
At close: Mar 03, 2025, 3:59 PM
4.35
2.11%
After-hours: Mar 03, 2025, 07:29 PM EST
No 1D chart data available
| Bid | 4.2 |
| Market Cap | 380.7M |
| Revenue (ttm) | 155.66K |
| Net Income (ttm) | -39.2M |
| EPS (ttm) | -0.44 |
| PE Ratio (ttm) | -9.68 |
| Forward PE | -8.25 |
| Analyst | Buy |
| Ask | 4.79 |
| Volume | 721,776 |
| Avg. Volume (20D) | 1,937,446 |
| Open | 4.53 |
| Previous Close | 4.52 |
| Day's Range | 4.25 - 4.59 |
| 52-Week Range | 2.30 - 5.05 |
| Beta | 0.88 |
About TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo P...
Industry Biotechnology
Sector Healthcare
IPO Date May 7, 2019
Employees 27
Stock Exchange NASDAQ
Ticker Symbol TRVI
Analyst Forecast
According to 9 analyst ratings, the average rating for TRVI stock is "Buy." The 12-month stock price forecast is $7.5, which is an increase of 76.06% from the latest price.
Buy 88.89%
Hold 0.00%
Sell 0.00%
2 months ago
+15.83%
Trevi Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
2 months ago
+44.58%
Trevi Therapeutics shares are trading higher after the company announced positive outcomes for the treatment of patients from its chronic cough Phase 2b CORAL trial.
